ARTICLE | Company News
Pharmacyclics regains Optrin rights
October 17, 2001 7:00 AM UTC
PCYC regained from Alcon Laboratories (Fort Worth, Texas) global rights to develop and market Optrin motexafin lutetium to treat age-related macular degeneration (AMD) and other retinal diseases. In D...